TMCnet News
Research and Markets: Biologicals in Oncology Drug Pipeline Update 2015 - 980 Companies Plus Partners Developing 1676 Biological Drugs in 4119 Developmental ProjectsResearch and Markets (http://www.researchandmarkets.com/research/vk5jcm/biologicals_in) has announced the addition of the "Biologicals in Oncology Drug Pipeline Update 2015" report to their offering. This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 980 companies plus partners developing 1676 biological drugs in 4119 developmental projects in cancer. In addition, there are 26 suspended drugs and the accumulated number of cease drugs over the last years amount to another 1009 drugs. Biologicals In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 692 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 620 out of the 626 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 84 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
For more information visit http://www.researchandmarkets.com/research/vk5jcm/biologicals_in
|
